title: [The significance of age and sex for the absence of immune response to hepatitis B vaccination].
abstract: BACKGROUND
  Seroepidemiological investigations after the administration of hepatitis B vaccine have shown that even 15% of vaccinated healthy persons do not generate immune response to the vaccines currently in use.
  
  
  OBJECTIVE
  The aim of the research is to test the immunogenicity of hepatitis B vaccine in different age groups on the adult vaccinated population sample in Serbia.
  
  
  METHODS
  The tested general population sample consisted of 154 adult subjects. Immunization was done using the recombinant fungal vaccine obtained by genetic engineering (Euvax B vaccine, manufacturer LG, distributor Sanofi Pasteur). All tested subjects in the research received 1 ml of hepatitis B vaccine administered intramuscularly into the deltoid muscle by 0, 1, 6 schedule.
  
  
  RESULTS
  In the tested sample, 3.13% of persons aged up to 29 years, 6.25% aged 30-35 year and 19.23% of the tested persons aged 40 years and older had no immune response. The relative risk of"no response"findings was twice higher in the group aged 30-39 as compared to the population aged up to 29 years. The detected risk was six times higher for the population of 40 years and older in comparison to the population aged up to 29 years. Also, the relative risk of"no response" findings for the population of 40 years and older was more than three times higher than for the group aged 30-39. Absent immune response in relation to sex was found to be higher in male subjects.
  
  
  CONCLUSIONS
  The rates of"no response"finding was the following: 3.13% in the group aged up to 29 years, 6.25% in the group aged 30-39, as well as in the group aged 40 years and older (19.23%). Immune response in relation to age groups was statistically significantly different (p<0.001), while there was a statistically significant correlation (C=0.473; p<0.001) between the age of the subjects and the immune response. In relation to sex, the "no response"finding was found to be increased in the males, but without any statistically significant difference (p>0.05).
authors.forename: Ilija
authors.initials: I
authors.lastname: Rosić
authors.forename: Sead
authors.initials: S
authors.lastname: Malićević
authors.forename: Snezana
authors.initials: S
authors.lastname: Medić
mesh_terms: D000328:Adult; D000375:Aging / Q000276:immunology; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008297:Male; D012727:Sex Characteristics; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: C484909:Euvax-B; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic